Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
Status:
Terminated
Trial end date:
2016-12-22
Target enrollment:
Participant gender:
Summary
This study will primarily evaluate the safety and efficacy of andecaliximab in adults with
active Crohn's disease. The study will consist of a Double-Blind Phase of 8 weeks followed by
an Open-Label Extension. Participants who complete the Double-Blind Phase will be eligible to
enroll in the optional Open-Label Extension for an additional 44 weeks. Participants who
complete Week 52 assessments will be eligible to enter the Extended Treatment Phase to
continue treatment with andecaliximab for an additional 156 weeks.